Article
Targeting senescent cells by dasatinib and quercetin ameliorates postmenopausal osteoporosis and rejuvenates bone regeneration.
2022-04-06
Abstract excerpt
Clinical therapies developed for estrogen-deficiency-driven postmenopausal osteoporosis (PMO) and related diseases, such as bone degeneration, show multiple adverse effects nowadays. Targeting senescent cells (SnCs) and the consequent senescence-associated secretory phenotype (SASP) with a combination of dasatinib and quercetin (DQ) is a recently developed novel therapy for multiple age-related diseases. Herein, w...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- eb1d2681-8c24-5381-a71b-e35f5005dd0d
- DOI
- 10.21203/rs.3.rs-1444778/v1
